SHS Gesellschaft für Beteiligungsmanagement mbH
20. May 2020 - Newsletter

Internationally approved innovation for ventilatory support from Germany

Medical technology

TNI Medical AG (SHS III Fund)

The availability of sufficient ventilatory support capacity for COVID-19 patients is an extremely critical issue for most of the healthcare systems worldwide. Products by TNI Medical AG, of Würzburg, Germany, contribute to this effort.

The innovative technology developed by TNI for the non-invasive ventilatory support (high-flow therapy) of patients can be of critical assistance in helping patients who are severely ill with COVID-19. This is how TNI is helping to stabilize healthcare systems during the coronavirus crisis. The product has since been granted approvals in Europe, the US and China. TNI has operations in all of the core regions hardest hit by COVID-19. The device by TNI is not a substitute for an invasive ventilator for the patients who are most severely affected, but it does provide relief to hospital patients who are not yet suffering life-threatening respiratory distress. In the US, due to the high death rate in invasively ventilated patients (> 70-80%), investigations are under way to determine whether early, non-invasive ventilatory support with the aid of high-flow therapy offers a better approach for these patients. In addition to its use with COVID-19 patients, TNI’s ventilatory-support device is used mainly in the treatment of COPD (chronic obstructive pulmonary disease) in the hospital and home settings. According to the WHO, COPD is the third most common cause of death in the world.

Since March 2020 a subsidiary of an international medtech group, TNI is currently preparing to boost its production capacity to meet global demand.

More information: